Tezspire meets primary endpoints in Phase III EoE trial CROSSING

AstraZeneca reported on August 27, 2026 that the Phase III CROSSING trial of Tezspire (tezepelumab) in eosinophilic esophagitis (EoE) hit its co-primary and all key secondary endpoints. The trial showed that Tezspire produced statistically significant benefits over placebo on both co-primary measures and every key secondary endpoint at week 24, with those effects holding up through week 52 across both doses studied.¹

The two co-primary endpoints were histologic remission and the frequency and severity of dysphagia, measured against placebo.¹ The company said Tezspire's safety profile in the trial was generally consistent with its already approved indications.¹

The study design, per CROSSING's trial registry entry, was a randomized, double-blind, placebo-controlled Phase III trial. It enrolled 368 patients aged 12 to 80 with symptomatic and histologically active EoE, randomized 1:1:1 to receive either a low or high dose of Tezspire or placebo.¹ Histologic remission was defined as a peak esophageal eosinophil count of six or fewer per high-power field, and the second co-primary endpoint used the Dysphagia Symptom Questionnaire, scored from zero to 84, with higher scores indicating worse symptoms.¹

AstraZeneca said it plans to present full results at an upcoming medical meeting and share them with regulatory authorities.¹ Tezspire is developed jointly by AstraZeneca and Amgen. Under their collaboration, the companies split costs and profits evenly after AstraZeneca pays Amgen a mid-single-digit inventor royalty, with AstraZeneca leading development and Amgen leading manufacturing.¹ Tezspire is currently approved for severe asthma in more than 70 countries and for chronic rhinosinusitis with nasal polyps in the US, EU, China and Japan.¹ The FDA granted tezepelumab Orphan Drug Designation for EoE in October 2021.¹